Chief Medical Officer
Title: Chief Medical Officer.
Education: Doctor of Philosophy (PhD) in medicine from Copenhagen University. Master’s degree in medicine from Copenhagen University.
Background: Former Medical Director at Genmab, TopoTarget and Zealand Pharma in the development and research fields, Denmark. Medical Manager in the medical marketing field at Abbott Denmark. Advisor at Novo Nordisk and Nycomed Denmark.
Shares in Medivir: 0
Warrants in Medivir: 0
Title: Interim Chief Financial Officer.
Education: MBA from Växjö University.
Background: Since 2009 working with interim assignments. Most recently, three assignments in a row, as CFO for Private Equity owned companies facing transition or transformation. Prior to these roles, a broad experience in finance and business administration most notably gained as Head of Accounting & Reporting at Skanska Nya Hem, Finance Director at Lantmännen Agroetanol and BA Controller at Ikea Industries Russia.
President and CEO
Title: President and CEO
Education: PhD at Uppsala University.
Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public, multibillion dollar company. In the 1990s, he held senior positions at Astra AB, prior to which he was a Professor of Organic Chemistry at Uppsala University.
Other directorships: Chairman of the Boards of Cerecor Inc., and Adhera Therapeutics, and Member of the Boards of InDex Pharmaceuticals AB, Beactica AB and Uppsala University.
Shares in Medivir: 9,000
Executive Vice President Strategic Business Development
Title: Executive Vice President Strategic Business Development
Education: Ph. D. in physical chemistry from Royal Institute of Technology and Executive MBA from Stockholm University.
Background: Former CEO of Modus Therapeutics. Prior to that Director, Corporate Development in Sobi. Responsible to build and lead the function Project & Portfolio Management in Biovitrum. Also Member of the Boards of PCI Biotech and Idogen.
Shares in Medivir: 5,000 class B
Warrants in Medivir: 4,630